文献速递胸部肿瘤

PROSPECT-LUNG:推动癌症临床试验务实创新的国家临床试验网络试验

PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.
PubMed 文献 · J Thorac Oncol · 2026-02-24

PROSPECT-Lung(CTIU2317-A082304-S2402)是一项务实、III期、开放标签、随机试验,在可切除非小细胞肺癌患者中比较围手术期与辅助免疫治疗策略的3年真实世界无事件生存期和总生存期。与同疾病领域的A081801试验相比,方案长度从88页降至30页(65%),每患者数据字段从2523降至438(82.6%),估计站点工作量从210小时/患者降至36.5小时/患者,完全入组时可节省超过190,000小时。

要点

  • PROSPECT-Lung采用简化入排标准、精简方案和数据收集的务实设计。
  • 方案长度减少65%,数据字段减少82.6%,站点工作量从210小时降至36.5小时/患者。
  • 完全入组时预计节省超过190,000小时图表审查、数据录入等工作。

核心结论

  • 通过拓宽入排标准和精简物流,PROSPECT-Lung在保持科学严谨性的同时减轻患者、研究者和站点负担。

研究设计与样本

  • PROSPECT-Lung(CTIU2317-A082304-S2402)是一项务实、III期、开放标签、随机试验,比较可切除非小细胞肺癌患者的围手术期与辅助免疫治疗策略。

主要发现

  • 与A081801相比,PROSPECT-Lung方案长度从88页降至30页(65%),每患者数据字段从2523降至438(82.6%)。
  • 站点工作量从A081801的210小时/患者估计降至PROSPECT-Lung的36.5小时/患者。
  • 完全入组时相当于在图表审查、数据录入、文档和质量控制方面节省超过190,000小时。

临床怎么用

  • 在适当且可能时,采用务实方法设计癌症临床试验可提高效率、可及性和真实世界相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Clinical trial designs marked by extensive data collection, restrictive eligibility, and lengthy protocols create inefficiencies, increase costs, and hinder accrual. These are further compounded by staffing shortages and operational burdens. By incorporating pragmatic features, including simplified eligibility criteria, streamlined protocol, and data collection, the PROSPECT-Lung trial, CTIU2317-A082304-S2402 Perioperative versus Adjuvant Systemic Therapy in Patients with Resectable NSCLC, paves the way forward as a model for enhancing clinical trial efficiency and feasibility, while maintaining scientific rigor. METHODS: PROSPECT-Lung (CTIU2317-A082304-S2402) is a pragmatic, phase III, open-label, randomized trial comparing 3-year real-world event-free survival and overall survival using approved perioperative and adjuvant immunotherapy-based treatment strategies in patients with resectable NSCLC. Protocol length and data collection elements were compared with Alliance A081801, Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST CHEMO-IO (ClinicalTrials.gov Identifier: NCT04267848), a phase III trial in the same disease setting, to quantify streamlining efforts. RESULTS: Relative to A081801, PROSPECT-Lung achieved major reductions in trial complexity. Protocol length decreased from 88 to 30 pages (65%), and data fields per patient were reduced from 2523 to 438 (82.6%), driven by streamlined summary versus cycle-by-cycle data collection. These efficiencies translate to estimated site workload reductions from 210 hours per patient in A081801 to 36.5 hours in PROSPECT-Lung. At full accrual, this equates to more than 190,000 hours saved in chart review, data entry, documentation, and quality control. CONCLUSION: By broadening eligibility and streamlining logistics, PROSPECT-Lung reduces burden for patients, investigators, and sites while preserving scientific integrity. This pragmatic approach, when appropriate and possible, provides a replicable model for future cancer trials, promoting efficiency, accessibility, and real-world relevance. GOV IDENTIFIER: NCT06632327 (CTIU2317-A082304-S2402).

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Booth A, Hillman S, Laumann K, et al. PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials. J Thorac Oncol. 2026. PMID: 41747891. doi:10.1016/j.jtho.2026.103650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。